Bookmark Kaumudi Online  Bookmark this site  Editor@Kaumudi  |  Marketing  Print Advt rates  |  Calendar 2012        Go!    
 
 
February 26, Sunday 2017 8:13 PM       

       HEADLINES: Attack on actress: Prime accused brought to Coimbatore for evidence collection                                              Kunhalikutty selected League national general secretary                                              Afghanistan: ISIS recruit from Kerala killed in drone strike                                              Attack on actress: Probe should be handed over to trusted agency                                              Two killed in bus-car collision                                              South Indian comedian Thavakkala dies                                              India needs more scientists to harness technology: Modi                                              Gujarat ATS arrests suspected ISIS operatives                                              PIA had seven passengers standing during Karachi-Madina flight                                              Kohli, Ashwin unmoved in latest ICC Test Rankings                                              Kaumudi Facebook
       SCI&TECH Next Article: Mysterious 'Higgs Bison' species identified  
       Male birth control shots may lower pregnancy odds: study
 
         Posted on :19:04:16 Oct 28, 2016
   
A A
       Last edited on:19:04:16 Oct 28, 2016
         Tags: Male birth control, lower pregnancy odds, stu
 
GENEVA: An experimental birth control vaccine for men can effectively prevent pregnancy in their female partners by lowering sperm count, scientists including those from India have found. Researchers are working to perfect the combination of hormonal contraceptives to reduce the risk of mild to moderate side effects, including depression and other mood disorders.
 
"The study found it is possible to have a hormonal contraceptive for men that reduces the risk of unplanned pregnancies in the partners of men who use it," said Mario Philip Reyes Festin, from the World Health Organisation (WHO) in Switzerland. "Our findings confirmed the efficacy of this contraceptive method previously seen in small studies," said Festin.
 
Researchers, including Man Mohan Misro of the National Institute of Health and Family Welfare in New Delhi, tested the safety and effectiveness of injectable contraceptives in 320 healthy men ages 18 to 45.
 
The participants had all been in monogamous relationships with female partners between the ages of 18 and 38 for at least a year. The men underwent testing to ensure they had a normal sperm count at the start of the study.
 
The men received injections of 200 milligrams of a long-acting progestogen called norethisterone enanthate (NET-EN) and 1,000 milligrams of a long-acting androgen called testosterone undecanoate (TU) for up to 26 weeks to suppress their sperm counts.
 
Healthcare professionals gave the men two injections every eight weeks. Participants initially provided semen samples after eight and 12 weeks in the suppression phase and then every 2 weeks until they met the criteria for the next phase.
 
During this time, the couples were instructed to use other non-hormonal birth control methods. Once a participant's sperm count was lowered to less than one million/ml in two consecutive tests, the couple was asked to rely on the injections for birth control.
 
During this period known as the efficacy phase of the study, the men continued to receive injections every eight weeks for up to 56 weeks. Participants provided semen samples every eight weeks to ensure their sperm counts stayed low. Once the participants stopped receiving the injections, they were monitored to see how quickly their sperm counts recovered.
 
The hormones were effective in reducing the sperm count to one million/ml or less within 24 weeks in 274 of the participants. The contraceptive method was effective in nearly 96 per cent of continuing users. Only four pregnancies occurred among the men's partners during the efficacy phase of the study.
 
Researchers stopped enrolling new participants in the study in 2011 due to the rate of adverse events, particularly depression and other mood disorders, reported by the participants. The men reported side effects including injection site pain, muscle pain, increased libido and acne. The study was published in the Journal of Clinical Endocrinology and Metabolism.
A A
       SCI&TECH
Next Article: Mysterious 'Higgs Bison' species identified
 
 
SCI&TECH HEADLINES
NASA may put astronauts on deep space test flight  
Juno to remain in current orbit around Jupiter: NASA  
US man receives new face from donor  
Over 100 new potential planets spotted  
ISRO to launch record 104 satellites on Feb 15  
Now, video-makers can live stream on YouTube  
Music, drugs stimulate same part of brain: study  
Facebook adds tool for helping in times of crisis  
Moon may have formed from collision of tiny 'moonlets'  
China to set up world's highest altitude telescopes in Tibet  
NASA to launch two robotic probes to study early solar system  
After Mars, ISRO eyes Venus and Jupiter  
New, rare galaxy spotted over 359 mln light-years away  
Coconut sized tumor removed from Iraqi woman's head  
Bacteria-powered battery built on single sheet of paper  
'Human-made objects on Earth amount to 30 trillion tonnes'  
Element 117 officially named 'Tennessine'  
Predatory bacteria may wipe out 'superbugs': study  
New potent vaccine may spell end for HIV  
Water exists deeper in Earth than thought: study  
Docs reconstruct tongue with flesh from thigh  
Why wounds take longer to heal with age decoded  
WhatsApp launches video calling to take on Google Duo, Skype  
Molecules on phone can unveil your lifestyle: study  
Chandrayaan-2 mission: ISRO conducts tests for Moon landing  
 
Do you suspect controversy behind attack on the actress?
Yes
 
No
 
Don't kow
 
 
 
Home Kerala India World Business Sports Sci&Tech Education Automobile CityNews Movies Environment Letters 
© Copyright keralakaumudi Online 2011  |  Reproduction in whole or in part without written permission is prohibited.
Head Office Address: Kaumudi Buildings, Pettah P.O, Trivandrum - 695024, India.
Online queries talk to Deepu Sasidharan, + 91 98472 38959 or Email deepu[at]kaumudi.com
Customer Service -Advertisement Disclaimer Statement   |  Copyright Policy